Coherus Oncology (CHRS) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Coherus Oncology (CHRS) over the past year, losing 49.5% versus a loss of 68.1%. Coherus Oncology is the larger company by market cap ($57.1 million vs $56.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | OKYO |
|---|---|---|
| Share price | $0.3698 | $1.07 |
| Market cap | $57.15M | $56.15M |
| 1-day change | -4.47% | -7.76% |
| YTD return | -73.96% | -48.31% |
| 1-year return | -68.12% | -49.53% |
| 5-year return | -97.99% | — |
| EPS (TTM) | $-1.12 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $42.17M | — |
| Revenue growth (YoY) | +59.81% | — |
| Net income (latest FY) | $168.02M | $-4.71M |
| Gross margin | 67.24% | — |
| Operating margin | -429.51% | — |
| Net margin | 398.43% | — |
| 52-week high | $2.62 | $3.20 |
| 52-week low | $0.3628 | $1.00 |
| Distance from 52-week high | -85.86% | -66.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1995.73% | +678.50% |
| Average volume | 1.80M | 143.41K |
| Shares outstanding | 154.54M | 52.48M |
| Employees | 144 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed CHRS by 18.6 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
CHRS vs OKYO FAQ
Which is bigger, Coherus Oncology or OKYO Pharma?
Coherus Oncology (CHRS) is larger, with a market capitalization of $57.15M compared with $56.15M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, CHRS or OKYO?
OKYO returned -49.53% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.